Fixed-Dose Combination

Achieving Additional Efficacy

Because trabodenoson is a novel mechanism that works through the trabecular meshwork, the primary fluid outflow path in the eye, we believe it could complement other existing mechanisms for the treatment of glaucoma. In fact, IOP lowering studies in preclinical models conducted by our team and collaborators have shown that IOP lowering is significantly improved when trabodenoson is combined with other glaucoma products, as compared to these products alone*.

Inotek has conducted a Phase 2 trial in patients with ocular hypertension (OHT) or primary open-angle glaucoma (POAG) in which trabodenoson eye drops were co-administered with eye drops of latanoprost, a market-leading prostaglandin analog whose mechanism of action is at the uveoscleral pathway, or secondary outflow facility. We are currently conducting a Phase 2 trial in similar patients, where a combination of trabodenoson and latanoprost is administered in a single eye drop.

*Presented at the 2014 ARVO Meeting (Association for Research in Vision and Ophthalmology). Session Title: Neurodegeneration and neuroprotection; Presentation Title: Evaluation of the neuroprotective effects of trabodenoson in a model of acute ocular hypertension.